OPTIMIZING NON-ADDICTIVE DRUG DELIVERY WORLDWIDE

IN THE MANAGEMENT OF PAIN AND CNS DISORDERS

Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate.

Our transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to optimize the efficacy of our non-addictive pain management pipeline and our CNS disorder pipeline. Our goal is for each product candidate to become the standard of care in their respective Therapeutic sectors. Our business objective is to commercialize products that will be supported by respective medical societies, and advocacy groups, as well as be regarded by insurance companies, prescribers, pharmacists and hospitals.

Virpax® Pharmaceuticals (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.

NOVEL DRUG-DELIVERY SYSTEMS

Molecular Envelope Technology (MET)

Virpax uses the patented MET to deliver drug molecules to the brain while protecting these selected molecules from degradation during their intranasal transport past the blood-brain barrier.

Watch video

We’re developing molecules with the MET to deliver treatment options for the management of:

Liposomal in Hydrogel encapsulation

Virpax uses a patented injectable liposomal hydrogel encapsulation to deliver a local anesthetic at the wound/incision site providing pain control for 96 hours.

We’re using liposomal hydrogel encapsulation to develop a local anesthetic for:

Topical spray film

Virpax uses a patented spray film technology to deliver drug molecules intended for localized administration without the messy handling or creams and gels.

We’re using the proprietary topical spray film technology to develop an anti-inflammatory agent to manage pain associated with:

Recent Press Releases

VIEW MORE

Recent Media

  • Apr 27, 2022

  • [VIDEO] Virpax appears on 6abc Philadelphia

    Mar 29, 2022

  • Mar 15, 2022

VIEW MORE

Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic.

FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management lasting up to 30 days, in response to some form of tissue injury, such as trauma or surgery.
February 2022
The accelerating development of new treatments and devices are top six on the FDA priority list.  
February 2022

OUR MISSION

Our mission is to use our proprietary delivery systems to optimize the efficacy of our non‑addictive pain and CNS disorder product candidates. 

We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological disorders worldwide.

CalloutWE'RE WORKING TOADVANCE NON-ADDICTIVE DRUG DELIVERY WORLDWIDE

EXPERIENCED

EXECUTIVE LEADERSHIP

Learn more

ROBUST

PIPELINE

Learn more

OPTIMIZING DRUG-DELIVERY

In the Treatment of Pain and CNS Disorders

Envelta™

Molecular Envelope Enkephalin Powder

Envelta is an intranasal enkephalin powder formulation being studied to manage severe post cancer pain and non-cancer pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.

More about Envelta

Probudur™

Injectable liposomal hydrogel Bupivacaine

Virpax will introduce its proprietary Probudur, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; longer than any other liposomal bupivacaine.

More about Probudur

Epoladerm™

Topical Diclofenac Spray Film

Epoladerm nonclinical studies have demonstrated improved drying times and less messy handling compared to topical gels/ointments. It’s an invisible application, therefore, more aesthetically appealing. Its pliable application allows for optimized use on contours of the knees.

More about Epoladerm

AnQlar™

High-density molecular masking spray

AnQlar is a high-density molecular masking intranasal spray, being developed as an anti-viral barrier to help prevent the risk of viral spread of SARS and influenza for up to 24 hours.

More about AnQlar

VRP324

Molecular Envelope Cannabidiol Powder

VRP324 is a pharmaceutical-grade cannabidiol intranasal spray being studied for the management of Epilepsy in adults and children, a Rare Pediatric Disease.

More about VRP324

We are pairing effective medical treatments with our transforming drug-delivery platforms

Virpax’s proprietary pipeline is well positioned to meet unmet needs in multi-billion dollar markets.

View our pipeline
virpax pharma pain management mission

EXPLORE OUR

MISSION

new pain management solutions

DISCOVER OUR

PRODUCTS

Pain Management - Team

MEET OUR

TEAM

virpax pharmaceutical contact

LET’S

CONNECT